Rani Therapeutics Holdings, Inc. RANI
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a cardio-renal-metabolic drug developer. Its lead program, RT-114 (RaniPill HC with PG-102 bispecific GLP-1/GLP-2 agonist), is in Phase 1 for Obesity. Its next catalyst on record is RT-114: Start of Phase 1b repeat-dose study in patients with obesity (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: RT-114 — Start of Phase 1b repeat-dose study in patients with obesity (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RT-114 (RaniPill HC plus PG-102) | Obesity | device-combination | Phase 1 |
| RaniPill GO (completed three Phase 1 trials with prior candidates) | Oral delivery of peptides/biologics | device-combination | Phase 1 |
| Chugai antibody for hemophilia in RaniPill HC (partnered) | Hemophilia | device-combination | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
- Seismic Therapeutic, Inc. Unknown
- Tenaya Therapeutics, Inc. TNYA
- iBio, Inc. IBIO
- Scynexis Inc SCYX
- Aspire-Lakewood Holdings, Inc. ASBP
- Lexaria Bioscience Corp. LEXX
- PMGC Holdings Inc. ELAB
- Revelation Biosciences, Inc. REVB
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.